Development and Validation of Novel Cell-free Direct Neutralization Assay for SARS-CoV-2

Ji Youn Lim, Alyssa Fiore, Bruce Le, Corinne Minzer, Halle White, Krystle Burinski, Humaira Janwari, David J. Wright, Sasha Perebikovsky, Ralph Davis, David Okrongly, Aravind Srinivasan

This paper introduces a novel, high-throughput method for measuring SARS-CoV-2 neutralizing antibodies that bypasses the need for live virus and high-containment laboratories. By utilizing a clever "decoy" fusion protein to filter out non-neutralizing antibodies, the researchers created a cell-free assay that correlates strongly with gold-standard live-virus tests while being faster, safer, and easier to standardize.

TL;DR

Researchers developed the Q-NAb IgG Test, a cell-free assay that quantifies SARS-CoV-2 neutralizing antibodies (NAbs) in a standard BSL-2 environment. The test uses a novel fusion protein to sequester non-neutralizing antibodies, allowing for direct, variant-specific NAb measurement that is fully traceable to WHO International Standards.

What Problem Does This Paper Address?

Measuring neutralizing antibodies—the subset of antibodies that actually block viral entry—is the "gold standard" for assessing immunity. However, the traditional Microneutralization Assay (MNA) requires culturing live virus, which necessitates Biosafety Level 3 (BSL-3) facilities, takes days to complete, and suffers from poor reproducibility between labs.

While "surrogate" assays exist, they are often qualitative or have a limited dynamic range. Furthermore, as the virus evolves, many existing tests calibrated for the ancestral strain fail to accurately measure protection against newer variants like Omicron. There is a critical need for a quantitative, standardized, and variant-adaptable test that can be run in a standard clinical lab (BSL-2).

Methods

The core innovation is a novel Fusion Protein (FP).

  • The Design: The FP consists of the SARS-CoV-2 Spike Receptor Binding Domain (RBD) "docked" to the human ACE2 protein.
  • The "Closed" Configuration: The researchers engineered a disulfide bridge to lock the RBD and ACE2 together. This hides the Receptor Binding Motif (RBM)—the specific site where neutralizing antibodies bind—while leaving the rest of the RBD exposed.
  • The Assay Workflow:
    1. Pre-blocking: A clinical sample is incubated with the FP. The FP acts as a decoy, binding and "sequestering" non-neutralizing antibodies (NNAbs).
  • Direct Binding: The mixture is added to a 96-well plate coated with variant-specific RBD. Because the NNAbs are already bound to the FP, only the "free" neutralizing antibodies (which couldn't bind the hidden RBM on the FP) are available to bind to the plate.
  • Detection: Bound NAbs are measured using a fluorescently labeled secondary antibody.
  • Standardization: The assay is calibrated against WHO International Standards (NIBSC 21/340 and 21/338), converting raw signals into International Units (IU/mL).

Datasets

The study validated the assay using several cohorts:

  • Ancestral Strain Validation: 207 samples, including 137 post-vaccination (mRNA), 51 convalescent, and 19 pre-pandemic negatives.
  • Omicron BA.4/5 Validation: 200 samples, including 151 post-bivalent booster, 20 convalescent, and 29 pre-pandemic negatives.
  • Monoclonal Panel: A set of 14 commercially available neutralizing and non-neutralizing monoclonal antibodies to verify the specificity of the fusion protein blocking mechanism.

Key Insights and Ideas

  • Selective Depletion: The "aha moment" is using the docked RBD-ACE2 complex to physically differentiate antibody types. By hiding the "business end" (the RBM) of the protein, the researchers created a filter that only lets neutralizing antibodies through to the final detection step.
  • Modular RBD Backbone: The researchers used a conserved RBD backbone and only swapped out the RBM mutations for different variants. This allows for high-yield protein production and makes the platform easily adaptable to future "Variants of Concern."
  • Standardization is Key: By tying results to WHO International Units, the authors address a major pain point in COVID-19 research: the inability to compare NAb titers across different studies and labs.

Key Results

  • Strong Correlation: The Q-NAb test showed excellent agreement with live-virus MNA, with Spearman’s correlation coefficients ($\rho$) of 0.87 for the Ancestral strain and 0.92 for Omicron BA.5.
  • High Sensitivity: Both versions of the kit achieved >94% sensitivity in detecting NAbs in vaccinated or previously infected individuals.
  • Analytical Performance: The assay demonstrated a wide dynamic range (e.g., 300–32,000 IU/mL for BA.4/5) and high precision, with repeatability coefficients of variation (CV) between 3% and 8%.
  • Interference Resistance: The test results were not affected by common blood "interferents" like bilirubin (icteric), lipids (lipemic), or hemoglobin (hemolyzed).

Limitations and Future Work

  • Specificity "Noise": The BA.4/5 assay showed lower specificity (54%) because it detected low-level neutralizing activity in pre-Omicron samples that the live-virus test missed. The authors suggest this might be due to the high sensitivity of their fluorescent detection.
  • Beyond Binding: The assay measures binding to the RBM as a proxy for neutralization. It does not account for other immune mechanisms, such as T-cell responses or antibody-dependent cellular cytotoxicity (ADCC).
  • Future Mutations: If future variants develop significant mutations outside the RBM that interfere with the Fusion Protein's stability, the "decoy" design may need to be updated.
  • Clinical Cutoffs: While the test provides a quantitative IU/mL value, the authors note that the scientific community still needs to define exactly what level of IU/mL constitutes "protection" for the latest variants.

Summary updated

Abstract

Abstract Neutralizing antibody titer elicited through infection or vaccination is accepted as a reliable surrogate for protection from SARS-CoV-2 infection, hospitalization, and mortality. The gold standard for measuring neutralizing antibody levels relies on culturing live virus in the presence of a target cell and quantitating the level where 50% of the target cells are infected. These assays have numerous technical challenges, not the least is the requirement for a BSL-3 laboratory to perform the live virus testing. We developed the Q-NAb IgG Test for the quantitative determination of neutralizing antibodies against SARS-CoV-2 variants, traceable to WHO International Standards. The test utilizes a novel Fusion Protein that mimics the Spike receptor binding domain docked to the human ACE2 protein and effectively blocks non-neutralizing antibodies in the sample. After pre-blocking sequesters the non-neutralizing antibodies from the samples, direct binding of the residual neutralizing antibodies to variant RBDs coated in the wells of the microtiter plate is measured with a fluorescent secondary antibody. Results of the Q-NAb IgG Test agree with a live virus Microneutralization Assay for both the Ancestral strain (WA1-2020) and the Omicron BA.5 (COR-22-063113/2022) variant (Spearman’s correlation, ρ = 0.87 and 0.92, respectively). The analytical performance (LoB, LoD, LoQ, linearity, precision, and interference) of the Q-NAb IgG Test was established along with sensitivity and specificity using a panel of monoclonal neutralizing and non-neutralizing anti-SARS-CoV-2 antibodies. Clinical sensitivity and specificity using pre-pandemic, convalescent, and vaccinated serum and plasma samples is also reported. The advantages of the Q-NAb IgG Test are its strong correlation to live virus neutralization tests, traceability to WHO International Standards, convenient microtiter plate format, low sample volume requirements, and suitability for a BSL-2 laboratory.
BibTeX
@article{lim2025development,
  author = {Ji Youn Lim and Alyssa Fiore and Bruce Le and Corinne Minzer and Halle White and Krystle Burinski and Humaira Janwari and David J. Wright and Sasha Perebikovsky and Ralph Davis and David Okrongly and Aravind Srinivasan},
  title = {{Development and Validation of Novel Cell-free Direct Neutralization Assay for SARS-CoV-2}},
  journal = {Journal of Virological Methods},
  year = {2025},
  doi = {10.1016/j.jviromet.2025.115201},
}
Figure